Zeit | Aktuelle Nachrichten | ||
---|---|---|---|
18.04. | Estetrol by Mithra Pharmaceuticals for Female Sexual Dysfunction: Likelihood of Approval | ||
18.04. | Estetrol by Mithra Pharmaceuticals for Genitourinary Syndrome of Menopause (GSM): Likelihood of Approval | ||
18.04. | Abatacept by Bristol-Myers Squibb for Myocarditis: Likelihood of Approval | ||
18.04. | Tezepelumab by Amgen for Chronic Obstructive Pulmonary Disease (COPD): Likelihood of Approval | ||
18.04. | Paclitaxel albumin bound by Bristol-Myers Squibb for Gallbladder Cancer: Likelihood of Approval | ||
17.04. | IGM and Sanofi collaboration will pivot to immunology and inflammation | ||
17.04. | Lexeo wins fast track designation for Friedreich's ataxia gene therapy | ||
17.04. | Leading providers of washing, disinfection and sterilisation equipment and services | ||
17.04. | Alvotech and Teva gain FDA approval of Selarsdi for psoriasis | ||
17.04. | Johnson & Johnson reports net earnings of $5.3bn in Q1 2024 | ||
17.04. | TetraScience and Google Cloud link for AI-driven drug developments | ||
17.04. | Medincell and AbbVie make injectable therapy development deal | ||
16.04. | Risk adjusted net present value: What is the current valuation of Novo Nordisk's NN-9931? | ||
16.04. | Risk adjusted net present value: What is the current valuation of Eli Lilly and Co's LY-3972406? | ||
16.04. | Risk adjusted net present value: What is the current valuation of Pfizer's PF-07275315? | ||
16.04. | Risk adjusted net present value: What is the current valuation of Enliven Therapeutics's ELVN-002? | ||
16.04. | Risk adjusted net present value: What is the current valuation of AstraZeneca's AZD-9574? | ||
16.04. | Risk adjusted net present value: What is the current valuation of Novartis's XXB-750? | ||
16.04. | Risk adjusted net present value: What is the current valuation of Novo Nordisk's NNC0519-0130? | ||
16.04. | Risk adjusted net present value: What is the current valuation of AstraZeneca's Sabestomig? | ||
16.04. | Jardiance and Ofev propel Boehringer's human pharma sales | ||
16.04. | Acorda loses Nasdaq listing to cap biotech's end | ||
16.04. | Harnessing artificial intelligence and digital technologies across the biopharma value chain | ||
16.04. | Two major breakthroughs in Fragile X Syndrome treatments | ||
16.04. | Leading API biologics (cell, gene, vaccine and virus) companies in contract manufacturing |